Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8‐day regimen for treatment of low‐risk gestational trophoblastic neoplasia

We aimed to compare weekly methotrexate (MTX) regimen and methotrexate‐folinic acid (MTX‐FA) 8‐day regimen in the first line treatment of low‐risk gestational trophoblastic neoplasia (GTN).

[1]  R. Berkowitz,et al.  Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. , 2020, Gynecologic oncology.

[2]  G. Tulunay,et al.  Factors Related to Treatment Outcomes in Low-risk Gestational Neoplasia , 2017, Tumori.

[3]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[4]  J. Lurain,et al.  Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. , 2016, Gynecologic oncology.

[5]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  R. Berkowitz,et al.  Response to Chemotherapy in Overweight/Obese Patients With Low-Risk Gestational Trophoblastic Neoplasia , 2015, International Journal of Gynecologic Cancer.

[7]  M. Hasanzadeh,et al.  Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia. , 2014, Journal of cancer research and therapeutics.

[8]  R. Coleman,et al.  The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. , 2013, European journal of cancer.

[9]  N. Sebire,et al.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Gilani,et al.  The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. , 2013, Journal of cancer research and therapeutics.

[11]  A. Lim,et al.  Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia , 2012, British Journal of Cancer.

[12]  M. Seckl,et al.  The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1 , 2010, British Journal of Cancer.

[13]  N. Sebire,et al.  CURRENT ISSUES IN THE HISTOPATHOLOGY OF GESTATIONAL TROPHOBLASTIC TUMORS , 2010, Fetal and pediatric pathology.

[14]  A. Sharifi,et al.  Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  A. Schott,et al.  [Evaluation of treatment relating to gestational trophoblastic tumor registered to the French Trophoblastic Disease Reference Center (TDRC) in Lyon from 1999 to 2005]. , 2007, Gynecologie, obstetrique & fertilite.

[16]  A. Schott,et al.  What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. , 2006, Gynecologic oncology.

[17]  A. Mitsuhashi,et al.  Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. , 2005, Gynecologic oncology.

[18]  G. Rustin,et al.  Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  M. Rettenmaier,et al.  Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease , 1988, Obstetrics and gynecology.

[21]  E. Newlands,et al.  Central nervous system metastases of choriocarcinoma. 23 Years' experience at Charing Cross Hospital , 1983, Cancer.